Volta

Biomarkers and point of care screening approaches for the management of preeclampsia

Unknown authors · 2024
hash_id: a961fe28390c7dceee0735a0eebc73380159e3c1df11768528e26ac3ac55db84 · DOI: 10.1038/s43856-024-00642-4

Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease. Ng, Chaturvedi et al. discuss established, emerging, and promising biomarkers related …

Reference & gravity metrics

Citations
0
Citations / yr
0.00
RCR
Mass
0.00
Depth
0.00
Momentum
0.000
Burn rate
0.00 ATP/day
Start price
25.00 ATP

Secondary-market trade history

No secondary-market trades recorded for this Volta yet.

References (0)

No outbound references recorded.

Cited by (1)

Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection secondary